We are live on ! Find out more
DCMM

DG Capital Management (Massachusetts) Portfolio holdings

AUM $102M
1-Year Est. Return 29.14%
This Fund
S&P 500
This Quarter Est. Return
+5.67%
1 Year Est. Return
+29.14%
3 Year Est. Return
+96.74%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$166M
AUM Growth
-$109K
Cap. Flow
-$7.01M
Cap. Flow %
-4.23%
Top 10 Hldgs %
29.78%
Holding
76
New
12
Increased
23
Reduced
29
Closed
11

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$3.02M
2
CSIQ icon
Canadian Solar
CSIQ
+$2.54M
3
ULTA icon
Ulta Beauty
ULTA
+$2.21M
4
BMY icon
Bristol-Myers Squibb
BMY
+$1.6M
5
ABBV icon
AbbVie
ABBV
+$1.46M

Top Sells

Rank Stock Value
1
CB icon
Chubb
CB
+$2.79M
2
TXN icon
Texas Instruments
TXN
+$2.45M
3
AMGN icon
Amgen
AMGN
+$2.42M
4
HAR
Harman International Industries
HAR
+$2.32M
5
TSN icon
Tyson Foods
TSN
+$1.89M

Sector Composition

Rank Sector Weight
1 Healthcare 39.3%
2 Financials 15.77%
3 Technology 11.18%
4 Communication Services 8.59%
5 Industrials 8.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BIIB icon
1
Biogen
BIIB
$29.9B
$8.03M 4.84%
19,874
+2,090
+12% +$839K
LLY icon
2
Eli Lilly
LLY
$1.07T
$6.46M 3.9%
77,435
-1,660
-2% -$126K
V icon
3
Visa
V
$677B
$4.74M 2.86%
70,655
+7,495
+12% +$508K
AMGN icon
4
Amgen
AMGN
$203B
$4.65M 2.8%
30,285
-15,108
-33% -$2.42M
GILD icon
5
Gilead Sciences
GILD
$161B
$4.5M 2.71%
38,400
+1,075
+3% +$117K
BMY icon
6
Bristol-Myers Squibb
BMY
$127B
$4.25M 2.56%
63,905
+24,330
+61% +$1.6M
MA icon
7
Mastercard
MA
$477B
$4.24M 2.55%
45,345
+3,575
+9% +$328K
HCA icon
8
HCA Healthcare
HCA
$84.8B
$4.21M 2.54%
46,423
+7,880
+20% +$631K
ABBV icon
9
AbbVie
ABBV
$458B
$4.21M 2.54%
62,650
+22,435
+56% +$1.46M
NKE icon
10
Nike
NKE
$61.9B
$4.13M 2.49%
76,542
-660
-0.9% -$33.8K
NVS icon
11
Novartis
NVS
$295B
$4.04M 2.43%
45,840
-2,427
-5% -$223K
ADBE icon
12
Adobe
ADBE
$89.5B
$3.88M 2.34%
47,939
-9,665
-17% -$754K
AAPL icon
13
Apple
AAPL
$4.89T
$3.78M 2.28%
120,520
-2,880
-2% -$92.1K
GS icon
14
Goldman Sachs
GS
$313B
$3.77M 2.27%
18,065
+305
+2% +$62.1K
FDX icon
15
FedEx
FDX
$74.5B
$3.65M 2.2%
21,415
-3,975
-16% -$692K
BMRN icon
16
BioMarin Pharmaceuticals
BMRN
$11.5B
$3.33M 2.01%
+24,345
New +$3.02M
AGN
17
DELISTED
Allergan plc
AGN
$3.3M 1.99%
10,888
+90
+0.8% +$26.8K
TWX
18
DELISTED
Time Warner Inc
TWX
$3.29M 1.98%
37,625
-680
-2% -$58K
RCPT
19
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$3.28M 1.98%
17,255
+5,890
+52% +$973K
NFLX icon
20
Netflix
NFLX
$292B
$3.27M 1.97%
347,900
-96,250
-22% -$805K
AAL icon
21
American Airlines Group
AAL
$9.58B
$3.08M 1.86%
77,094
-11,958
-13% -$545K
AET
22
DELISTED
Aetna Inc
AET
$2.87M 1.73%
22,542
+465
+2% +$53.1K
META icon
23
Meta Platforms (Facebook)
META
$1.51T
$2.87M 1.73%
33,478
-6,675
-17% -$545K
MJN
24
DELISTED
Mead Johnson Nutrition Company
MJN
$2.83M 1.71%
31,370
-8,670
-22% -$836K
BHC icon
25
Bausch Health
BHC
$1.65B
$2.8M 1.69%
12,620
+2,290
+22% +$508K
1
2 3 4

Similar funds

LOT
Lombard Odier Transatlantic Montreal, Quebec, Canada $105M AUM 10.28% 1-Year Est. Return
BGA
Belmont Global Advisors Dallas, Texas $106M AUM 2.89% 1-Year Est. Return
PCM
Panning Capital Management New York $97.5M AUM 302.5% 1-Year Est. Return
EDRAML
Edmond de Rothschild Asset Management (Luxembourg) Luxembourg $95.2M AUM 19.45% 1-Year Est. Return
EC
Eachwin Capital New York $108M AUM 14.45% 1-Year Est. Return
SAMNY
Samsung Asset Management (New York) New York $109M AUM 14.34% 1-Year Est. Return
BCCM
Blue Clay Capital Management Minneapolis, Minnesota $88.7M AUM 6.88% 1-Year Est. Return
EIAM
Equinox Institutional Asset Management Princeton, New Jersey $87.9M AUM 1.01% 1-Year Est. Return

DG Capital Management (Massachusetts)'s Q2 2015 Portfolio in Review

As of Q2 2015, DG Capital Management (Massachusetts) held 76 positions worth $166M, down 0.07% from $166M the previous quarter. Its ten largest holdings account for 30% of the portfolio.

DG Capital Management (Massachusetts) withdrew a net $7.01M in Q2 2015, closing 11 positions and reducing 29 holdings. Its most notable exit was Chubb, an estimated $2.79M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 39% of assets, up from 37% a quarter earlier, followed by Financials and Technology.

Against the trend, DG Capital Management (Massachusetts) opened a new position in BioMarin Pharmaceuticals worth $3.33M.

  • DG Capital Management (Massachusetts)'s largest Q2 2015 buy was BioMarin Pharmaceuticals: 24,345 shares worth $3.33M.
  • DG Capital Management (Massachusetts) added most to Bristol-Myers Squibb in Q2 2015, an estimated $1.6M increase.
  • DG Capital Management (Massachusetts)'s biggest Q2 2015 reduction was Amgen, cutting an estimated $2.42M.
  • DG Capital Management (Massachusetts) fully exited Chubb in Q2 2015, selling an estimated $2.79M.
  • DG Capital Management (Massachusetts)'s ten largest holdings make up 30% of its $166M portfolio in Q2 2015.
  • DG Capital Management (Massachusetts) opened 12 new positions and closed 11 in Q2 2015.
  • DG Capital Management (Massachusetts)'s portfolio value fell 0.07% quarter-over-quarter to $166M.

Based on DG Capital Management (Massachusetts)'s 13F filing for Q2 2015, filed 11 Aug 2015.